Literature DB >> 10587982

Long-term follow-up in hematopoietic stem-cell transplant patients.

V L Fisher1.   

Abstract

Hematopoietic stem-cell transplantation (HSCT) has increasingly become an accepted treatment for many childhood diseases and disorders. Potential HSCT recipients can be children with hematological malignancies or solid tumors, as well as congenital and acquired disorders. In the past decade, the use of HSCT in the treatment of pediatric disorders has grown exponentially while advances in supportive care have improved survival rate, contributing to a rapidly growing population of transplant survivors. Although numerous similarities can be found between pediatric and adult long-term HSCT survivors, this article provides a brief overview of the pediatric patients, emphasizing the aspects of surveillance and late effects. Understanding the long-term complications that can occur after HSCT is important in determining the appropriate evaluations and medical treatment for the patient involved. The goal of this article is to assist caregivers in providing optimal care for long-term survivors of HSCT. The initial section of this work comprises the three major causes of late effects in HSCT. It will then encompass a system review of the different potential complications that are seen with HSCT.

Entities:  

Mesh:

Year:  1999        PMID: 10587982     DOI: 10.1034/j.1399-3046.1999.00067.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  2 in total

Review 1.  Imaging of late complications of cancer therapy in children.

Authors:  Susan C Shelmerdine; Govind B Chavhan; Paul S Babyn; Paul C Nathan; Sue C Kaste
Journal:  Pediatr Radiol       Date:  2016-12-01

Review 2.  Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children's Oncology Group.

Authors:  Sharon Castellino; Andrew Muir; Ami Shah; Sheila Shope; Kevin McMullen; Kathy Ruble; Ashley Barber; Andrew Davidoff; Melissa M Hudson
Journal:  Pediatr Blood Cancer       Date:  2010-05       Impact factor: 3.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.